{"count": 4, "results": [{"_id": "34054309", "pmid": 34054309, "pmcid": "PMC8153069", "title": "Metformin Use and the Outcome of Metastatic Renal Cell Carcinoma Treated with Sunitinib or Pazopanib", "journal": "Cancer Manag Res", "authors": ["Fiala O", "Ostašov P", "Rozsypalová A", "Hora M", "Šorejs O", "Šustr J", "Bendová B", "Trávníček I", "Filipovský J", "Fínek J", "Büchler T"], "date": "2021-05-21T00:00:00Z", "doi": "10.2147/CMAR.S305321", "meta_date_publication": "2021", "meta_volume": "13", "meta_issue": "", "meta_pages": "4077-4086", "score": 50289.582, "text_hl": "The largest study focusing on the role of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ in @<m>DISEASE_Clear_cell_metastatic_renal_cell_carcinoma</m> @DISEASE_MESH:C538445 @@@mRCC@@@ in association with targeted therapy has been reported by Hamieh et al, who conducted a retrospective analysis of @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Clear_cell_metastatic_renal_cell_carcinoma</m> @DISEASE_MESH:C538445 @@@mRCC@@@ enrolled in Phase II and III clinical trials. ", "citations": {"NLM": "Fiala O, Ostašov P, Rozsypalová A, Hora M, Šorejs O, Šustr J, Bendová B, Trávníček I, Filipovský J, Fínek J, Büchler T. Metformin Use and the Outcome of Metastatic Renal Cell Carcinoma Treated with Sunitinib or Pazopanib Cancer Manag Res. 2021;13():4077-4086. PMID: 34054309", "BibTeX": "@article{34054309, title={Metformin Use and the Outcome of Metastatic Renal Cell Carcinoma Treated with Sunitinib or Pazopanib}, author={Fiala O and Ostašov P and Rozsypalová A and Hora M and Šorejs O and Šustr J and Bendová B and Trávníček I and Filipovský J and Fínek J and Büchler T}, journal={Cancer Manag Res}, volume={13}, pages={4077-4086}}"}}, {"_id": "27460432", "pmid": 27460432, "title": "Effect of Metformin Use on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma.", "journal": "Clin Genitourin Cancer", "authors": ["Hamieh L", "McKay RR", "Lin X", "Moreira RB", "Simantov R", "Choueiri TK"], "date": "2017-04-01T00:00:00Z", "doi": "10.1016/j.clgc.2016.06.017", "meta_date_publication": "2017 Apr", "meta_volume": "15", "meta_issue": "2", "meta_pages": "221-229", "score": 50073.375, "text_hl": "Effect of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ Use on Survival Outcomes in @SPECIES_9606 @@@Patients@@@ With @<m>DISEASE_Clear_cell_metastatic_renal_cell_carcinoma</m> @DISEASE_MESH:C538445 @@@Metastatic Renal Cell Carcinoma@@@.", "citations": {"NLM": "Hamieh L, McKay RR, Lin X, Moreira RB, Simantov R, Choueiri TK. Effect of Metformin Use on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer. 2017 Apr;15(2):221-229. PMID: 27460432", "BibTeX": "@article{27460432, title={Effect of Metformin Use on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma.}, author={Hamieh L and McKay RR and Lin X and Moreira RB and Simantov R and Choueiri TK}, journal={Clin Genitourin Cancer}, volume={15}, number={2}, pages={221-229}}"}}, {"_id": "27211307", "pmid": 27211307, "title": "Metformin Use and Outcome of Sunitinib Treatment in Patients With Diabetes and Metastatic Renal Cell Carcinoma.", "journal": "Clin Genitourin Cancer", "authors": ["Keizman D", "Ish-Shalom M", "Sella A", "Gottfried M", "Maimon N", "Peer A", "Hammers H", "Eisenberger MA", "Sinibaldi V", "Neiman V", "Rosenbaum E", "Sarid D", "Mermershtain W", "Rouvinov K", "Berger R", "Carducci MA"], "date": "2016-10-01T00:00:00Z", "doi": "10.1016/j.clgc.2016.04.012", "meta_date_publication": "2016 Oct", "meta_volume": "14", "meta_issue": "5", "meta_pages": "420-425", "score": 50064.55, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ Use and Outcome of @CHEMICAL_Sunitinib @CHEMICAL_MESH:D000077210 @@@Sunitinib@@@ Treatment in @SPECIES_9606 @@@Patients@@@ With @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@Diabetes@@@ and @<m>DISEASE_Clear_cell_metastatic_renal_cell_carcinoma</m> @DISEASE_MESH:C538445 @@@Metastatic Renal Cell Carcinoma@@@.", "citations": {"NLM": "Keizman D, Ish-Shalom M, Sella A, Gottfried M, Maimon N, Peer A, Hammers H, Eisenberger MA, Sinibaldi V, Neiman V, Rosenbaum E, Sarid D, Mermershtain W, Rouvinov K, Berger R, Carducci MA. Metformin Use and Outcome of Sunitinib Treatment in Patients With Diabetes and Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer. 2016 Oct;14(5):420-425. PMID: 27211307", "BibTeX": "@article{27211307, title={Metformin Use and Outcome of Sunitinib Treatment in Patients With Diabetes and Metastatic Renal Cell Carcinoma.}, author={Keizman D and Ish-Shalom M and Sella A and Gottfried M and Maimon N and Peer A and Hammers H and Eisenberger MA and Sinibaldi V and Neiman V and Rosenbaum E and Sarid D and Mermershtain W and Rouvinov K and Berger R and Carducci MA}, journal={Clin Genitourin Cancer}, volume={14}, number={5}, pages={420-425}}"}}, {"_id": "31995997", "pmid": 31995997, "title": "Management of metabolic adverse effects of everolimus in patients with renal carcinoma.", "journal": "Cas Lek Cesk", "authors": ["Gregorová J", "Holečková P", "Žáková K"], "date": "2019-01-01T00:00:00Z", "meta_date_publication": "2019 Winter", "meta_volume": "158", "meta_issue": "7-8", "meta_pages": "300-305", "score": 50057.375, "text_hl": "@CHEMICAL_Fenofibrate @CHEMICAL_MESH:D011345 @@@Fenofibrate@@@, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@, and @CHEMICAL_Everolimus @CHEMICAL_MESH:D000068338 @@@everolimus@@@ have several similar effects on intracellular level, therefore the effect of @CHEMICAL_Fenofibrate @CHEMICAL_MESH:D011345 @@@fenofibrate@@@ and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ in treating @CHEMICAL_Everolimus @CHEMICAL_MESH:D000068338 @@@everolimus@@@ induced @DISEASE_Metabolic_Diseases @DISEASE_MESH:D008659 @@@metabolic adverse@@@ effects in @<m>DISEASE_Clear_cell_metastatic_renal_cell_carcinoma</m> @DISEASE_MESH:C538445 @@@metastatic renal cell carcinoma@@@ @SPECIES_9606 @@@patients@@@ may be limited. ", "citations": {"NLM": "Gregorová J, Holečková P, Žáková K. Management of metabolic adverse effects of everolimus in patients with renal carcinoma. Cas Lek Cesk. 2019 Winter;158(7-8):300-305. PMID: 31995997", "BibTeX": "@article{31995997, title={Management of metabolic adverse effects of everolimus in patients with renal carcinoma.}, author={Gregorová J and Holečková P and Žáková K}, journal={Cas Lek Cesk}, volume={158}, number={7-8}, pages={300-305}}"}}]}